8-K
filed February 22, 2023, 6:59 PM ET
ticker UTHR
CIK 0001082554
earnings
confidence high
sentiment positive
materiality 0.70
United Therapeutics reports record 2022 revenue of $1.94B, up 15% YoY; Q4 EPS $2.67
UNITED THERAPEUTICS Corp
2022-FY EPS reported
$15.00
revenue$1,936,300,000
- Full year total revenues $1.94B, up 15% YoY; net income $727.3M ($15.00 diluted EPS).
- Q4 revenues $491.5M, net income $132.1M ($2.67 diluted EPS).
- Tyvaso net product sales $873M for 2022, up 44% YoY driven by Tyvaso DPI launch and PH-ILD expansion.
- Treprostinil product sales grew 19% in 2022; company targets $4B revenue run rate by end of 2025.
- Unituxin sales declined 10% to $182.9M; Adcirca down 26% due to generic competition.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
UNITED THERAPEUTICS Corp reported Three Months Ended December 31, 2022 results: revenue $ 491.5, net income $ 132.1, EPS $ 2.67.
- Period
- Three Months Ended December 31, 2022
- Revenue
- $ 491.5
- Net income
- $ 132.1
- EPS
- $ 2.67
- Result
- reported results
Exact text from the filing
Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
UNITED THERAPEUTICS Corp reported Year Ended December 31, 2022 results: revenue $ 1,936.3, net income $ 727.3, EPS $ 15.00.
- Period
- Year Ended December 31, 2022
- Revenue
- $ 1,936.3
- Net income
- $ 727.3
- EPS
- $ 15.00
- Result
- reported results
Exact text from the filing
Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.